ReviewPsoriasis (Auckland, N.Z.)2016
Current knowledge on psoriasis and autoimmune diseases.
Review in Psoriasis (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 3 syntheses or guidelines pooled it, 265 citations in OpenAlex.
- Efficacy and safety of mirikizumab (LY3074828) in chronic plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Pooled it
- Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.Journal of the American Academy of Dermatology · 2020Pooled it
- Sodium R-lipoate protects against psoriatic skin inflammation via modulating IL-23/IL-17A axis, oxidative stress, and mast cell activation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Spatially Profiling Trace Cytokine Signatures From Microscopically Derived Skin Samples to Probe Skin Disease Inflammation.Small methods · 2026Article
- Long-term postmarketing safety of psoriasis treatments on autoimmune disease risk: a 15-year nationwide cohort study in Denmark.Skin health and disease · 2026Article
- Immune Roles of Canonically Non-Immune Cells in Biomaterials Response.Cell biomaterials · 2026Article
- Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.AAPS PharmSciTech · 2026Review
- Correlations between Psoriasis Area and Severity Index (PASI), body mass index (BMI), smoking, and alcohol consumption in patients with psoriasis - a Romanian study.Journal of medicine and life · 2026Observational
- Microbiological analysis of patients with inverse and plaque-type psoriasis.BMC microbiology · 2025Article
- Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Psoriasis and Alopecia: Unveiling the Links.Dermatology practical & conceptual · 2025Review
- Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China.BMC health services research · 2025Article
- CD163/CD63+ Monocyte-Derived DC Profiled in Tissue by Multi-Antigen Analysis (MAA) Discriminate Chronic Eczema and Psoriasis.International journal of molecular sciences · 2025Article
- Toward Long-Acting Psoriasis Therapy with Phloretin-Loaded Microneedle Patches: Insights fromACS pharmacology & translational science · 2025Article
- Epidemiological Profile of Psoriasis and Linked Comorbidities in Chinese Population at Shenzhen: A Cross-Sectional Study.Health science reports · 2025Article
- Recent advancement of fisetin-based nanoformulations in the management of psoriasis.Discover nano · 2025Review
- A complete sojourn on nanotechnological advancements and nanocarrier applications in psoriasis management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A Promising Approach to Psoriasis Vulgaris Management with N-Acetylcysteine and Vitamin E: Targeting the Interplay of Inflammatory and Oxidative Stress.Biomedicines · 2025Article
- Adipose tissue may not be a major player in the inflammatory pathogenesis of Autism Spectrum Disorder.Brain, behavior, & immunity - health · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Psoriasis is a prevalent, chronic inflammatory disease of the skin, mediated by crosstalk between epidermal keratinocytes, dermal vascular cells, and immunocytes such as antigen presenting cells (APCs) and T cells. Exclusive cellular "responsibility" for the induction and maintenance of psoriatic plaques has not been clearly defined. Increased proliferation of keratinocytes and endothelial cells in conjunction with APC/T cell/monocyte/macrophage inflammation leads to the distinct epidermal and vascular hyperplasia that is characteristic of lesional psoriatic skin. Despite the identification of numerous susceptibility loci, no single genetic determinant has been identified as responsible for the induction of psoriasis. Thus, numerous other triggers of disease, such as environmental, microbial and complex cellular interactions must also be considered as participants in the development of this multifactorial disease. Recent advances in therapeutics, especially systemic so-called "biologics" have provided new hope for identifying the critical cellular targets that drive psoriasis pathogenesis. Recent recognition of the numerous co-morbidities and other autoimmune disorders associated with psoriasis, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus suggest common signaling elements and cellular mediators may direct disease pathogenesis. In this review, we discuss common cellular pathways and participants that mediate psoriasis and other autoimmune disorders that share these cellular signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.